The circulating levels of β2-GP1 INHIBIT tumor growth and exert antiangiogenic effect on melanomas, bladder cancer, and prostate cancer, suggesting that β2-GP1 is a potential marker of the efficacies of angiogenesis-targeted therapy and diagnosis (36–39). Here, APOH is linked to prostate cancer.